Advertisement
Advertisement
U.S. markets open in 3 hours 9 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Orphazyme A/S (DK0060910917.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
0.1798+0.0002 (+0.11%)
As of 08:10AM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1796
Open0.1798
Bid0.1775 x N/A
Ask0.1898 x N/A
Day's Range0.1798 - 0.1798
52 Week Range0.1798 - 0.1798
Volume0
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for DK0060910917.SG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks

      KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M

      KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.

    • Benzinga

      Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs

      Orphazyme A/S (NASDAQ: ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA enables us to consider the best possible path forward for arimoclomol," commented Orphazyme Chief Executive Officer Anders Vadsholt. The decision follows CHMP's negative trend vote on arimoclomol application following an Oral Explanation. Orp

    • Zacks

      Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug

      Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.

    Advertisement
    Advertisement